Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bcl-2 antisense therapy in multiple myeloma.

A Bloem1, H Lockhorst

  • 1Department of Immunology, University Hospital Utrecht, The Netherlands.

Pathologie-Biologie
|April 8, 1999
PubMed
Summary

Multiple myeloma drug resistance may be overcome by targeting the anti-apoptotic protein Bcl-2. Lowering Bcl-2 levels could chemosensitize cancer cells, offering a potential new therapy for this bone marrow cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dispersive Liquid-Liquid Microextraction for the Quantitation of Terpenes in Wine.

Journal of agricultural and food chemistry·2020
Same author

Confronting complex infections in a tertiary healthcare setting.

The Netherlands journal of medicine·2019
Same author

Natural skin surface pH is on average below 5, which is beneficial for its resident flora.

International journal of cosmetic science·2008
Same author

Vanillin production from simple phenols by wine-associated lactic acid bacteria.

Letters in applied microbiology·2007
Same author

A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms.

Cell death and differentiation·2005
Same author

Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.

Leukemia & lymphoma·2001

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma is a bone marrow plasma cell tumor.
  • Acquired chemotherapy drug resistance is nearly universal in myeloma patients.

Purpose of the Study:

  • To investigate the role of the anti-apoptotic protein Bcl-2 in multi-drug resistance in multiple myeloma.
  • To explore the potential of targeting Bcl-2 for chemosensitization therapy.

Main Methods:

  • Analysis of Bcl-2's role in myeloma drug resistance.
  • Evaluation of Bcl-2 reduction strategies, such as antisense treatment.

Main Results:

  • The anti-apoptotic protein Bcl-2 is implicated as a key factor in multi-drug resistance.
  • Reducing Bcl-2 levels makes myeloma cells more susceptible to chemotherapy-induced apoptosis.

Conclusions:

  • Targeting Bcl-2 may overcome drug resistance in multiple myeloma.
  • Bcl-2 antisense therapy holds promise for chemosensitizing myeloma cells in vivo.

Related Experiment Videos